These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 15696426

  • 1. [Metabotropic glutamate receptors: new molecular targets in the treatment of neurological and psychiatric diseases].
    Luján-Miras R.
    Rev Neurol; ; 40(1):43-53. PubMed ID: 15696426
    [Abstract] [Full Text] [Related]

  • 2. Metabotropic glutamate receptor 7: at the interface of cognition and emotion.
    O'Connor RM, Finger BC, Flor PJ, Cryan JF.
    Eur J Pharmacol; 2010 Aug 10; 639(1-3):123-31. PubMed ID: 20371242
    [Abstract] [Full Text] [Related]

  • 3. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs.
    Bruno V, Battaglia G, Copani A, D'Onofrio M, Di Iorio P, De Blasi A, Melchiorri D, Flor PJ, Nicoletti F.
    J Cereb Blood Flow Metab; 2001 Sep 10; 21(9):1013-33. PubMed ID: 11524608
    [Abstract] [Full Text] [Related]

  • 4. Metabotropic glutamate 1 receptor: current concepts and perspectives.
    Ferraguti F, Crepaldi L, Nicoletti F.
    Pharmacol Rev; 2008 Dec 10; 60(4):536-81. PubMed ID: 19112153
    [Abstract] [Full Text] [Related]

  • 5. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.
    Chaki S.
    Eur J Pharmacol; 2010 Aug 10; 639(1-3):59-66. PubMed ID: 20371240
    [Abstract] [Full Text] [Related]

  • 6. Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy.
    Alexander GM, Godwin DW.
    Epilepsy Res; 2006 Sep 10; 71(1):1-22. PubMed ID: 16787741
    [Abstract] [Full Text] [Related]

  • 7. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators.
    Ritzén A, Mathiesen JM, Thomsen C.
    Basic Clin Pharmacol Toxicol; 2005 Oct 10; 97(4):202-13. PubMed ID: 16176554
    [Abstract] [Full Text] [Related]

  • 8. Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders.
    Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R.
    Behav Pharmacol; 2003 Jul 10; 14(4):257-77. PubMed ID: 12838033
    [Abstract] [Full Text] [Related]

  • 9. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.
    Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD.
    Nat Rev Drug Discov; 2005 Feb 10; 4(2):131-44. PubMed ID: 15665858
    [Abstract] [Full Text] [Related]

  • 10. [Nicotine acetylcholine receptors and neuropsychiatric disorders].
    Vázquez-Palacios G, Bonilla-Jaime H.
    Rev Neurol; 2005 Feb 10; 39(12):1146-60. PubMed ID: 15625635
    [Abstract] [Full Text] [Related]

  • 11. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system.
    Schoepp DD.
    J Pharmacol Exp Ther; 2001 Oct 10; 299(1):12-20. PubMed ID: 11561058
    [Abstract] [Full Text] [Related]

  • 12. Mood disorders: regulation by metabotropic glutamate receptors.
    Pilc A, Chaki S, Nowak G, Witkin JM.
    Biochem Pharmacol; 2008 Mar 01; 75(5):997-1006. PubMed ID: 18164691
    [Abstract] [Full Text] [Related]

  • 13. Exciting times beyond the brain: metabotropic glutamate receptors in peripheral and non-neural tissues.
    Julio-Pieper M, Flor PJ, Dinan TG, Cryan JF.
    Pharmacol Rev; 2011 Mar 01; 63(1):35-58. PubMed ID: 21228260
    [Abstract] [Full Text] [Related]

  • 14. Dynamics and modulation of metabotropic glutamate receptors.
    Rondard P, Pin JP.
    Curr Opin Pharmacol; 2015 Feb 01; 20():95-101. PubMed ID: 25529199
    [Abstract] [Full Text] [Related]

  • 15. Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.
    Lesage A, Steckler T.
    Eur J Pharmacol; 2010 Aug 10; 639(1-3):2-16. PubMed ID: 20371230
    [Abstract] [Full Text] [Related]

  • 16. Modulation by group I mGLU receptor activation and group III mGLU receptor blockade of locomotor responses induced by D1-like and D2-like receptor agonists in the nucleus accumbens.
    Rouillon C, Degoulet M, Chevallier K, Abraini JH, David HN.
    Brain Res; 2008 Mar 10; 1198():44-54. PubMed ID: 18261716
    [Abstract] [Full Text] [Related]

  • 17. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders?
    Nicoletti F, Bruno V, Copani A, Casabona G, Knöpfel T.
    Trends Neurosci; 1996 Jul 10; 19(7):267-71. PubMed ID: 8799968
    [Abstract] [Full Text] [Related]

  • 18. Metabotropic G-protein-coupled glutamate receptors as therapeutic targets.
    Pellicciari R, Costantino G.
    Curr Opin Chem Biol; 1999 Aug 10; 3(4):433-40. PubMed ID: 10419848
    [Abstract] [Full Text] [Related]

  • 19. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.
    Palucha A, Pilc A.
    Pharmacol Ther; 2007 Jul 10; 115(1):116-47. PubMed ID: 17582504
    [Abstract] [Full Text] [Related]

  • 20. Involvement of endocannabinoid signaling in the neuroprotective effects of subtype 1 metabotropic glutamate receptor antagonists in models of cerebral ischemia.
    Landucci E, Boscia F, Gerace E, Scartabelli T, Cozzi A, Moroni F, Mannaioni G, Pellegrini-Giampietro DE.
    Int Rev Neurobiol; 2009 Jul 10; 85():337-50. PubMed ID: 19607979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.